Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers



Status:Completed
Conditions:Gastrointestinal, Podiatry, Diabetes
Therapuetic Areas:Endocrinology, Gastroenterology, Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:9/26/2018
Start Date:July 2012
End Date:June 2018

Use our guide to learn which trials are right for you!

A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Amnion/Chorion Membrane (dHACM) Wound Graft in the Management of Diabetic Foot Ulcers

The objective of this study is to evaluate the percentage of patients with complete diabetic
foot ulcer (DFU) closure following up to 12 weeks of treatment with either dehydrated human
amnion/chorion membrane (dHACM) plus standard of care (SOC) or SOC alone.


Inclusion Criteria:

1. Male or female age 18 or older.

2. The patient is willing and able to provide informed consent and participate in all
procedures and follow up evaluations necessary to complete the study.

3. Patient's ulcer must be diabetic in origin with a size ranging from 1 to 25 cm2.
Debridement will be done prior to randomization, if clinically indicated.

4. Wounds should be diabetic foot ulcers located on the dorsal or plantar surface of the
foot.

5. Patients with Type 1 or 2 diabetes (criteria for the diagnosis of diabetes mellitus
per ADA).

6. Ulcer must be present for a minimum of 30 days before enrollment/randomization, with
documented failure of prior treatment to heal the wound (≤25% wound area reduction
after 14 consecutive days of therapy immediately prior to randomization when treated
with standard protocol of care).

7. Affected leg has been offloaded (removable walker or total contact cast) for >14
consecutive days prior to randomization.

8. Serum Creatinine less than 3.0mg/dl (within last 6 months).

9. HbA1c less than 12% within previous 60 days.

10. Patient has adequate circulation to the affected extremity, as demonstrated by one of
the following within the past 60 days:

- Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR

- ABIs with results of ≥0.7 and ≤1.2, OR

- Doppler arterial waveforms, which are triphasic or biphasic at the ankle of
affected foot.

11. Females of childbearing potential must be willing to use acceptable methods of
contraception (birth control pills, barriers, or abstinence).

Exclusion Criteria:

1. Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive
probe-tobone will be confirmed when bone or joint can be felt with a sterile,
ophthalmological probe.

2. Patients with multiple wounds on the same foot where other wounds are within 3 cm of
the wound under care.

3. Patients considered not in reasonable metabolic control, confirmed by an HbA1c 12% or
greater at any time within previous 60 days.

4. Known history of poor compliance with medical treatments.

5. Patients currently enrolled in this study. Concurrent enrollment in the study is
prohibited.

6. Patients treated with investigational drug(s) or therapeutic device(s) within 30 days.

7. Patients currently receiving radiation therapy or chemotherapy.

8. Known or suspected local skin malignancy to the index diabetic ulcer.

9. Patients diagnosed with autoimmune connective tissue diseases.

10. Non-revascularizable surgical sites.

11. Active infection at index site or currently being treated with antibiotics

12. Any pathology that would limit the blood supply and compromise healing.

13. Patients that have received a biomedical or topical growth factor for their wound
within the previous 30 days. Study ulcer has been previously treated with tissue
engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g.
Oasis, Matristem) within the last 30 days.

14. Patients who are known to be pregnant, plan to become pregnant, or are breast feeding.

15. Known allergy to Gentamicin sulfate or Streptomycin sulfate.

16. Active Charcot deformity or major structural abnormalities of the foot.

17. Wounds that are greater than one year in duration without intermittent closure.
We found this trial at
20
sites
Sacramento, California 95628
Phone: 800-363-1069
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bakersfield, California 93309
Principal Investigator: Mark F Miller, DPM
Phone: 661-303-3444
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Birmingham, Alabama 35205
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Castro Valley, California 94546
Phone: 800-363-1069
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Columbia, South Carolina 29209
Principal Investigator: Delores Farrer, MD
Phone: 803-776-4000
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Eugene, Oregon 97401
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Framingham, Massachusetts 01702
?
mi
from
Framingham, MA
Click here to add this to my saved trials
Fresno, California 93720
Principal Investigator: Shawn Cazzell, DPM
Phone: 925-858-0714
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Fresno, California 93721
Principal Investigator: Shawn Cazzell, DPM
Phone: 559-431-1700
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Indio, California 92201
?
mi
from
Indio, CA
Click here to add this to my saved trials
Loma Linda, California 92357
Phone: 909-825-7084
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Los Angeles, California 90010
Phone: 213-365-0793
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
McAllen, Texas 78501
?
mi
from
McAllen, TX
Click here to add this to my saved trials
Murray, Utah 84157
Principal Investigator: William Tettelbach, MD
Phone: 801-507-9310
?
mi
from
Murray, UT
Click here to add this to my saved trials
Palm Springs, California 92262
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
8th Ave & C St
Salt Lake City, Utah 84143
(801) 408-1100
Principal Investigator: William Tettelbach, MD
Phone: 801-408-3638
LDS Hospital LDS Hospital provides clinical excellence to our community in a wide range of...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Alexander Reyzelman, DPM
Phone: 800-636-1069
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Toledo, Ohio 43606
Principal Investigator: Steven Gale, MD
Phone: 419-291-7182
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Virginia Beach, Virginia 23464
Principal Investigator: Patrick S Agnew, DPM
Phone: 757-523-0414
?
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Weymouth, Massachusetts
?
mi
from
Weymouth, MA
Click here to add this to my saved trials